Methylphenidate As a Treatment Option for Substance Use Disorder: a Transdiagnostic Perspective

Overview

Journal Front Psychiatry

Specialty Psychiatry

Date 2023 Aug 21

PMID 37599874

Authors

Peter van Ruitenbeek

Luisa Franzen

Natasha Leigh Mason

Peter Stiers

Johannes G Ramaekers

Affiliations

Soon will be listed here.

Abstract

A transition in viewing mental disorders from conditions defined as a set of unique characteristics to one of the quantitative variations on a collection of dimensions allows overlap between disorders. The overlap can be utilized to extend to treatment approaches. Here, we consider the overlap between attention-deficit/hyperactivity disorder and substance use disorder to probe the suitability to use methylphenidate as a treatment for substance use disorder. Both disorders are characterized by maladaptive goal-directed behavior, impaired cognitive control, hyperactive phasic dopaminergic neurotransmission in the striatum, prefrontal hypoactivation, and reduced frontal cortex gray matter volume/density. In addition, methylphenidate has been shown to improve cognitive control and normalize associated brain activation in substance use disorder patients and clinical trials have found methylphenidate to improve clinical outcomes. Despite the theoretical basis and promising, but preliminary, outcomes, many questions remain unanswered. Most prominent is whether all patients who are addicted to different substances may equally profit from methylphenidate treatment.

References

Onitsuka T, Oribe N, Kanba S . Neurophysiological findings in patients with bipolar disorder. Suppl Clin Neurophysiol. 2013; 62:197-206. DOI: 10.1016/b978-0-7020-5307-8.00013-2. View

Wilson S, Malone S, Venables N, McGue M, Iacono W . Multimodal indicators of risk for and consequences of substance use disorders: Executive functions and trait disconstraint assessed from preadolescence into early adulthood. Int J Psychophysiol. 2019; 163:47-57. PMC: 7302985. DOI: 10.1016/j.ijpsycho.2019.12.007. View

Houghton S, Douglas G, West J, Whiting K, Wall M, Langsford S . Differential patterns of executive function in children with attention-deficit hyperactivity disorder according to gender and subtype. J Child Neurol. 1999; 14(12):801-5. DOI: 10.1177/088307389901401206. View

Chase H, Eickhoff S, Laird A, Hogarth L . The neural basis of drug stimulus processing and craving: an activation likelihood estimation meta-analysis. Biol Psychiatry. 2011; 70(8):785-793. PMC: 4827617. DOI: 10.1016/j.biopsych.2011.05.025. View

Chmielewski W, Bluschke A, Bodmer B, Wolff N, Roessner V, Beste C . Evidence for an altered architecture and a hierarchical modulation of inhibitory control processes in ADHD. Dev Cogn Neurosci. 2019; 36:100623. PMC: 6969218. DOI: 10.1016/j.dcn.2019.100623. View

Nutt D, King L, Saulsbury W, Blakemore C . Development of a rational scale to assess the harm of drugs of potential misuse. Lancet. 2007; 369(9566):1047-53. DOI: 10.1016/S0140-6736(07)60464-4. View

Badgaiyan R, Sinha S, Sajjad M, Wack D . Attenuated Tonic and Enhanced Phasic Release of Dopamine in Attention Deficit Hyperactivity Disorder. PLoS One. 2015; 10(9):e0137326. PMC: 4589406. DOI: 10.1371/journal.pone.0137326. View

Chang L, Alicata D, Ernst T, Volkow N . Structural and metabolic brain changes in the striatum associated with methamphetamine abuse. Addiction. 2007; 102 Suppl 1:16-32. DOI: 10.1111/j.1360-0443.2006.01782.x. View

Kapur A . Is Methylphenidate Beneficial and Safe in Pharmacological Cognitive Enhancement?. CNS Drugs. 2020; 34(10):1045-1062. DOI: 10.1007/s40263-020-00758-w. View

10.

Madras B, Miller G, Fischman A . The dopamine transporter: relevance to attention deficit hyperactivity disorder (ADHD). Behav Brain Res. 2002; 130(1-2):57-63. DOI: 10.1016/s0166-4328(01)00439-9. View

11.

van den Brand F, Nagelhout G, Winkens B, Chavannes N, van Schayck O . Effect of a workplace-based group training programme combined with financial incentives on smoking cessation: a cluster-randomised controlled trial. Lancet Public Health. 2018; 3(11):e536-e544. DOI: 10.1016/S2468-2667(18)30185-3. View

12.

Solinas M, Belujon P, Fernagut P, Jaber M, Thiriet N . Dopamine and addiction: what have we learned from 40 years of research. J Neural Transm (Vienna). 2018; 126(4):481-516. DOI: 10.1007/s00702-018-1957-2. View

13.

Heinz A, Wrase J, Kahnt T, Beck A, Bromand Z, Grusser S . Brain activation elicited by affectively positive stimuli is associated with a lower risk of relapse in detoxified alcoholic subjects. Alcohol Clin Exp Res. 2007; 31(7):1138-47. DOI: 10.1111/j.1530-0277.2007.00406.x. View

14.

Shaw P, Lerch J, Greenstein D, Sharp W, Clasen L, Evans A . Longitudinal mapping of cortical thickness and clinical outcome in children and adolescents with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2006; 63(5):540-9. DOI: 10.1001/archpsyc.63.5.540. View

15.

Snyder H, Miyake A, Hankin B . Advancing understanding of executive function impairments and psychopathology: bridging the gap between clinical and cognitive approaches. Front Psychol. 2015; 6:328. PMC: 4374537. DOI: 10.3389/fpsyg.2015.00328. View

16.

Levin F, Evans S, Brooks D, Kalbag A, Garawi F, Nunes E . Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo. Drug Alcohol Depend. 2005; 81(2):137-48. DOI: 10.1016/j.drugalcdep.2005.06.012. View

17.

Chen M, Wu Y, Wu J, Fu Y, Li S, Liu H . Individual differences in inhibitory control abilities modulate the functional neuroplasticity of inhibitory control. Brain Struct Funct. 2019; 224(7):2357-2371. DOI: 10.1007/s00429-019-01911-y. View

18.

Sharma A, Couture J . A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD). Ann Pharmacother. 2013; 48(2):209-25. DOI: 10.1177/1060028013510699. View

19.

Wrase J, Grusser S, Klein S, Diener C, Hermann D, Flor H . Development of alcohol-associated cues and cue-induced brain activation in alcoholics. Eur Psychiatry. 2002; 17(5):287-91. DOI: 10.1016/s0924-9338(02)00676-4. View

20.

Noroozi A, Motevalian S, Zarrindast M, Alaghband-Rad J, Akhondzadeh S . Adding extended-release methylphenidate to psychological intervention for treatment of methamphetamine dependence: A double-blind randomized controlled trial. Med J Islam Repub Iran. 2021; 34:137. PMC: 7787037. DOI: 10.34171/mjiri.34.137. View